- Home
- JAZZ vs MKTX Comparison
JAZZ vs MKTX Comparison
Compare JAZZ & MKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- MKTX
- Stock Information
- Founded
- JAZZ 2003
- MKTX 2000
- Country
- JAZZ Ireland
- MKTX United States
- Employees
- JAZZ N/A
- MKTX N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- MKTX Investment Bankers/Brokers/Service
- Sector
- JAZZ Health Care
- MKTX Finance
- Exchange
- JAZZ Nasdaq
- MKTX Nasdaq
- Market Cap
- JAZZ 7.1B
- MKTX 8.1B
- IPO Year
- JAZZ 2007
- MKTX 2004
- Fundamental
- Price
- JAZZ $124.15
- MKTX $186.38
- Analyst Decision
- JAZZ Strong Buy
- MKTX Buy
- Analyst Count
- JAZZ 12
- MKTX 11
- Target Price
- JAZZ $182.75
- MKTX $228.09
- AVG Volume (30 Days)
- JAZZ 879.8K
- MKTX 663.2K
- Earning Date
- JAZZ 08-05-2025
- MKTX 08-06-2025
- Dividend Yield
- JAZZ N/A
- MKTX 1.61%
- EPS Growth
- JAZZ N/A
- MKTX N/A
- EPS
- JAZZ N/A
- MKTX 5.95
- Revenue
- JAZZ $4,086,695,000.00
- MKTX $837,157,000.00
- Revenue This Year
- JAZZ $5.65
- MKTX $7.10
- Revenue Next Year
- JAZZ $5.79
- MKTX $8.41
- P/E Ratio
- JAZZ N/A
- MKTX $31.71
- Revenue Growth
- JAZZ 4.52
- MKTX 7.67
- 52 Week Low
- JAZZ $95.49
- MKTX $183.00
- 52 Week High
- JAZZ $148.06
- MKTX $296.68
- Technical
- Relative Strength Index (RSI)
- JAZZ 66.76
- MKTX 35.49
- Support Level
- JAZZ $122.50
- MKTX $184.84
- Resistance Level
- JAZZ $126.14
- MKTX $192.96
- Average True Range (ATR)
- JAZZ 2.50
- MKTX 3.67
- MACD
- JAZZ 0.80
- MKTX 0.72
- Stochastic Oscillator
- JAZZ 87.44
- MKTX 18.97
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.